Patricia Lorusso, DO
Enriched profileAmy and Joseph Perella Professor of Medicine (Medical Oncology); Chief of Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics · Yale School of Medicine
Patricia Lorusso is Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief of Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics at Yale School of Medicine. OpenAlex indexes 1,281 publications with 34,992 citations (h-index 87); ClinicalTrials.gov lists 31 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Patricia M. LoRusso, DO, is Amy and Joseph Perella Professor of Medicine (Medical Oncology) at Yale School of Medicine / Yale Cancer Center. The public record shows 1,281 publications with 34,992 citations (h-index 87), centered on Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 31 registered clinical trials, industry payments reported by 22 companies, 4 NIH-funded awards (1995–2013).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 31 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 389.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 31 registered studies on ClinicalTrials.gov. The most recent:
- A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Sponsor: Incendia Therapeutics
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharma GmbH & Co.KGProgram year20256 payments$58,361openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20252 payments$20,160openpaymentsdata.cms.gov ↗
- Merck Healthcare KGaAProgram year20255 payments$17,221openpaymentsdata.cms.gov ↗
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 1995–2013 per NIH RePORTER. The latest:
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials Consortium
Yale University
FY2026$2,075,171UM1CA186689 - Multiplexed spatially resolved tissue biomarkers for optimal use of PD-1 axis blockers and PARP inhibitors in cancer.
Yale University
FY2025$251,360UH2CA271205
Congress activity
Updated 27 Aug 2026
272 congress contributions (2004–2026) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- Abstract CT075: Phase 1a/1b dose-escalation study of efbalropendekin alfa (XmAb24306) as single-agent and with atezolizumab in solid tumors
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.
Clinical and translational science
Clinical Trial2026 - From Biology to Bedside: Challenges and Strategies in Developing Combination Cancer Therapies in Early-Phase Trials.
Clinical cancer research
Review2026 - FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-in-Human Trials.
Clinical cancer research
Review2025 - FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers.
Clinical cancer research
Review2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaArticle1,112 citations2009
- 04Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449Article1,015 citations2009
- 05Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerArticle841 citations2015
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Patricia-Lorusso
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/aacr_foundation/p/C-8BOdbpjDX
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biospace.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- Former Co-Chair
NCI Cancer Therapy Evaluation Program (CTEP) Investigational Drug Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.yale.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Media & interviews
press, podcasts and appearances- Panelist
"People v. Cancer" symposium hosted by The Atlantic, discussing progress against cancer at AACR 2025
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
- Multiple recorded video interviews on OncLive discussing PARP inhibitors
genetic sequencing, and clinical trials
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Harlan Krumholz, MD
Yale School of Medicine
Eric Winer, MD
Yale School of Medicine
Roy Herbst, MD, PhD
Yale School of Medicine
Robert Rosenheck, MD
Yale School of Medicine